单位:[1]Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.医技科室影像中心核医学科首都医科大学附属北京友谊医院[2]Department of Surgical Oncology, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.首都医科大学附属北京儿童医院[3]Sinounion Medical Technology (Beijing) Co., Ltd., Beijing, China.[4]Department of Molecular Medicine and Pathology, School of Medical Science, The University of Auckland, Auckland, New Zealand.[5]Department of Laboratory Medicine of Medical School, Foshan University, Foshan, China.[6]Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China.
PurposeThis study aimed to assess the predictive ability of 18F-FDG PET/CT radiomic features for MYCN, 1p and 11q abnormalities in NB. MethodOne hundred and twenty-two pediatric patients (median age 3. 2 years, range, 0.2-9.8 years) with NB were retrospectively enrolled. Significant features by multivariable logistic regression were retained to establish a clinical model (C_model), which included clinical characteristics. 18F-FDG PET/CT radiomic features were extracted by Computational Environment for Radiological Research. The least absolute shrinkage and selection operator (LASSO) regression was used to select radiomic features and build models (R-model). The predictive performance of models constructed by clinical characteristic (C_model), radiomic signature (R_model), and their combinations (CR_model) were compared using receiver operating curves (ROCs). Nomograms based on the radiomic score (rad-score) and clinical parameters were developed. ResultsThe patients were classified into a training set (n = 86) and a test set (n = 36). Accordingly, 6, 8, and 7 radiomic features were selected to establish R_models for predicting MYCN, 1p and 11q status. The R_models showed a strong power for identifying these aberrations, with area under ROC curves (AUCs) of 0.96, 0.89, and 0.89 in the training set and 0.92, 0.85, and 0.84 in the test set. When combining clinical characteristics and radiomic signature, the AUCs increased to 0.98, 0.91, and 0.93 in the training set and 0.96, 0.88, and 0.89 in the test set. The CR_models had the greatest performance for MYCN, 1p and 11q predictions (P < 0.05). ConclusionsThe pre-therapy 18F-FDG PET/CT radiomics is able to predict MYCN amplification and 1p and 11 aberrations in pediatric NB, thus aiding tumor stage, risk stratification and disease management in the clinical practice.
第一作者单位:[1]Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
共同第一作者:
通讯作者:
通讯机构:[4]Department of Molecular Medicine and Pathology, School of Medical Science, The University of Auckland, Auckland, New Zealand.[5]Department of Laboratory Medicine of Medical School, Foshan University, Foshan, China.
推荐引用方式(GB/T 7714):
Qian Luodan,Yang Shen,Zhang Shuxin,et al.Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma via Pre-therapy 18F-FDG PET/CT Radiomics[J].FRONTIERS in MEDICINE.2022,9:doi:10.3389/fmed.2022.840777.
APA:
Qian Luodan,Yang Shen,Zhang Shuxin,Qin Hong,Wang Wei...&Yang Jigang.(2022).Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma via Pre-therapy 18F-FDG PET/CT Radiomics.FRONTIERS in MEDICINE,9,
MLA:
Qian Luodan,et al."Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma via Pre-therapy 18F-FDG PET/CT Radiomics".FRONTIERS in MEDICINE 9.(2022)